Although the advent of trastuzumab and other targeted therapy drugs has improved the prognosis and clinical outcome of HER2-positive breast cancer patients, drug resistance remains a challenging issue that necessitates alternative forms of treatment. This evidence concerns the gene ERBB2 and breast carcinoma.